Are Peptides Legal? What FDA Approval and

By Steve Levine · Updated October 16, 2026

Are peptides legal? It depends entirely on which peptide and how it reaches you. A handful are FDA-approved prescription drugs, a few others may be legally compounded by a pharmacy under narrow conditions, and most of the peptides sold online as “research chemicals” have no lawful route to being sold for human use at all. The rules also changed several times in 2026, so the date of any claim matters.

This guide explains how US federal law sorts peptides, what the FDA’s compounding “categories” are, and what changed between April and October 2026. It describes the law; it is not legal or medical advice.

Are peptides legal? Start with what the law calls a “drug”

“Peptide” is a chemistry word, not a legal category. Under the Federal Food, Drug, and Cosmetic Act, an article is a drug if it is intended to diagnose, cure, mitigate, treat or prevent disease, or intended to affect the structure or any function of the body. A peptide injected to build muscle, lose weight or heal an injury meets that definition, whatever the label calls it.

Size also matters. FDA regulations define a protein as an amino acid chain greater than 40 amino acids in size for the purposes of biologics rules. Most peptides discussed on this site are shorter than that, so they are handled under the ordinary drug rules: a new drug needs FDA approval before it can be marketed.

The four legal situations a peptide can be in

Situation	Example	Has FDA reviewed safety and effectiveness?	Lawful for human use?
FDA-approved drug	Semaglutide (Ozempic), first approved in the US in 2017	Yes, for the labeled uses	Yes, with a prescription, from a licensed pharmacy
Compounded from an eligible bulk substance	A pharmacy-made product under section 503A or 503B	No. Compounded drugs are not FDA-approved	Only if every statutory condition is met
Nominated substance under FDA evaluation	Substances on the 503A “Category 1” list	No	FDA says it does not intend to take action against compounding if specific conditions are met
Unapproved and not eligible	Retatrutide; peptides sold as “research use only”	No	No. FDA has warned sellers of these products

The approved row is the simplest. The Ozempic prescribing information describes semaglutide as a GLP-1 receptor agonist with a peptide backbone and lists its initial US approval as 2017. Approval covers the manufacturer’s product, made in inspected facilities, for the uses on the label. It does not extend to a powder from another source that contains, or claims to contain, the same molecule.

How compounding works, and where the bulk-substance categories fit

Compounding is a pharmacist or physician preparing a drug for an individual patient. Section 503A of the Act exempts compounded drugs from the approval requirement only if they are made from bulk drug substances that meet one of three tests. According to the FDA’s bulk drug substances page, the substance must comply with a USP or NF monograph if one exists; otherwise it must be a component of an FDA-approved drug; otherwise it must appear on the FDA’s 503A bulks list.

Most popular “wellness” peptides pass none of those tests: no monograph, no approved product, and no place on the final list. While it builds that list, the FDA sorts nominated substances into three interim categories, described in its interim policy guidance (January 2025 revision):

Category 1: under evaluation. The FDA says it does not intend to take action against compounding with these substances, but only if all of its conditions are met. Those include a manufacturer registered with the FDA and a valid certificate of analysis.
Category 2: substances that “raise significant safety risks.” The Category 1 policy does not apply to them.
Category 3: nominated without enough supporting information for the FDA to evaluate.

The categories are an enforcement policy, not an approval. A Category 1 substance has not been found safe or effective. The FDA is only signaling where it currently does not plan to act.

What changed in 2026

April 2026: many peptides left Category 2, without becoming eligible

The FDA had earlier placed a group of popular peptides in Category 2. Its Category 2 safety-risk page, current as of April 22, 2026, now lists BPC-157, TB-500, CJC-1295, melanotan II, AOD-9604, KPV, injectable GHK-Cu and several others as “nominated but withdrawn.” The nominators withdrew their nominations, so these substances came off the list.

That is easy to misread. The same page still records the FDA’s safety concerns for each one, for example that it “has identified no, or only limited, safety-related information” for BPC-157. The interim guidance says a withdrawal does “not reflect a determination by FDA” about the substance. A withdrawn substance is also not in Category 1, so the Category 1 enforcement policy does not cover it either.

Some peptides remain in Category 2. The page lists ipamorelin acetate, GHRP-2 and GHRP-6 under the outsourcing-facility (503B) policy, and kisspeptin-10 under 503A. All four were added on September 29, 2023. See the ipamorelin and CJC-1295 guide for what the FDA cited.

May 14, 2026: GHK-Cu partly restored

The FDA’s 503A category list (updated May 14, 2026) says GHK-Cu was removed from Category 1 on April 22, 2026. One nominator then clarified on May 5, 2026 that it meant to withdraw only the injectable route, so GHK-Cu “except for injectable routes of administration” went back into Category 1. Injectable GHK-Cu is not covered. The GHK-Cu guide explains why the route matters.

July 23-24, 2026: advisory committee meeting

A Federal Register notice published April 16, 2026 scheduled the Pharmacy Compounding Advisory Committee to discuss BPC-157, KPV, TB-500 and MOTS-c on July 23, and emideltide, Semax and epitalon on July 24, for possible inclusion on the 503A bulks list.

The FDA’s own briefing document proposed that none of them be added. For example: “FDA is proposing that BPC-157 (free base) NOT be included on the 503A Bulks List.” The FDA also wrote that it “does not intend to issue a final determination” until the committee’s input and all reviews are considered. A committee vote is advice to the agency, not a rule. As of October 15, 2026, the FDA meeting page lists briefing papers and presentations but no posted minutes or final determination.

October 14, 2026: a pending “interim access” policy

The federal regulatory review site shows that on October 14, 2026 the White House Office of Information and Regulatory Affairs received an FDA item titled “Interim Access Policy for Compounding Using Certain Peptides”, at the “Notice” stage. Its text has not been published, so which peptides it covers and on what terms is not yet public. Until the FDA issues it, the categories above remain the published position. Check the date on any article that says a peptide “is now legal.”

GLP-1 peptides: the shortage window has closed

Semaglutide and tirzepatide are approved drugs, so pharmacies could copy them only while they were in shortage. The FDA’s February 21, 2025 order declared the semaglutide injection shortage resolved. It gave 503A pharmacies until April 22, 2025 and outsourcing facilities until May 22, 2025 to wind down. An FDA update dated April 1, 2026 says neither drug appears on the shortage list or the 503B bulks list. The compounded semaglutide guide covers what that means for patients.

Unapproved GLP-1 peptides are a separate problem. The FDA states that retatrutide and cagrilintide “cannot be used in compounding under federal law”. It has also warned companies that sold semaglutide, tirzepatide, retatrutide, survodutide or mazdutide “falsely labeled ‘for research purposes’ or ‘not for human consumption.'” Read more in the retatrutide guide.

What “research use only” does and does not change

A disclaimer does not change what a product is. FDA regulations define intended use by “objective intent,” which can be shown by “labeling claims, advertising matter, or oral or written statements” and by the circumstances of distribution. A vial labeled for research but marketed with fat-loss claims and injection guides is being offered as a drug. The research-use-only guide covers this in detail.

What this means if you are deciding about a peptide

Approved does not mean every version is approved. Only the manufacturer’s product, dispensed on prescription, carries the FDA review.
Removed from Category 2 does not mean cleared. The April 2026 change followed withdrawn nominations, and the FDA’s recorded safety concerns still stand on its website.
A committee vote is not a rule. Status changes when the FDA publishes a final list, rule or policy.
Sports rules are separate. A peptide’s FDA status says nothing about whether athletes may use it. See the WADA prohibited list guide.

To check a specific substance yourself, open the FDA’s 503A category list and its Category 2 safety-risk page. The “updated” date at the top of each document tells you which version of the rules you are reading.

Sources

Owed money from a settlement? Check what is open at OpenClassActions.com. Caring for someone with dementia? Find practical guides at HelpDementia.com. Working out a skin routine? Evidence-based answers at AcneAdvocate.com. Forgot the name of a movie? Identify it at FindThisMovie.com. Was your data exposed? Track active breaches at DataBreachRadar.com.